AG˹ٷ

STOCK TITAN

[424B2] Citigroup Inc. Prospectus Supplement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

Key development: On 14 July 2025 GSK plc filed a Form 6-K reporting that the US FDA has accepted for review a supplemental application to extend the indication of its RSV vaccine, Arexvy, to adults aged 18-49 who have at least one risk factor for severe RSV.

Market opportunity: GSK estimates roughly 21 million US adults under 50 carry comorbidities such as COPD, asthma or heart disease that heighten RSV risk, materially enlarging the vaccine’s current target population (50+ at risk).

Clinical support: The filing is supported by Phase IIIb study NCT06389487 (n = 1,458). In adults 18-49 at increased risk, neutralising antibody titres met non-inferiority to those �60 years and safety/reactogenicity matched earlier Phase III data used for initial approval.

Regulatory timeline: FDA decision is expected in H1 2026. Parallel submissions are underway in the EU and Japan, signalling a coordinated global expansion strategy.

Strategic context: Arexvy already holds approval in >60 countries for adults �60 and in >50 markets for high-risk adults 50-59. Successful label expansion would secure first-mover advantage in an RSV segment with limited competition and could accelerate revenue growth.

Limitations: The announcement contains no sales guidance; commercial impact remains contingent on regulatory approval, ACIP recommendations and real-world uptake.

Sviluppo chiave: Il 14 luglio 2025 GSK plc ha presentato un modulo 6-K comunicando che la FDA statunitense ha accettato per la revisione una domanda supplementare per estendere l'indicazione del suo vaccino RSV, Arexvy, agli adulti di età compresa tra 18 e 49 anni con almeno un fattore di rischio per forme gravi di RSV.

Opportunità di mercato: GSK stima che circa 21 milioni di adulti statunitensi sotto i 50 anni presentino comorbidità come BPCO, asma o malattie cardiache che aumentano il rischio di RSV, ampliando significativamente la popolazione target attuale del vaccino (50+ a rischio).

Supporto clinico: La domanda è supportata dallo studio di Fase IIIb NCT06389487 (n = 1.458). Negli adulti 18-49 a rischio aumentato, i titoli di anticorpi neutralizzanti hanno dimostrato non inferiorità rispetto a quelli �60 anni e la sicurezza/reactogenicità è risultata in linea con i dati della precedente Fase III usata per l'approvazione iniziale.

Tempistiche regolatorie: La decisione della FDA è prevista per la prima metà del 2026. Sono in corso sottomissioni parallele nell'UE e in Giappone, indicando una strategia globale coordinata di espansione.

Contesto strategico: Arexvy è già approvato in oltre 60 paesi per adulti �60 anni e in più di 50 mercati per adulti ad alto rischio tra i 50 e 59 anni. L'espansione dell'indicazione assicurerebbe un vantaggio da pioniere in un segmento RSV con competizione limitata e potrebbe accelerare la crescita dei ricavi.

Limitazioni: L'annuncio non contiene previsioni di vendita; l'impatto commerciale dipenderà dall'approvazione regolatoria, dalle raccomandazioni ACIP e dall'adozione nel mondo reale.

Desarrollo clave: El 14 de julio de 2025, GSK plc presentó un Formulario 6-K informando que la FDA de EE.UU. ha aceptado para revisión una solicitud suplementaria para ampliar la indicación de su vacuna contra el RSV, Arexvy, a adultos de 18 a 49 años que tengan al menos un factor de riesgo para RSV grave.

Oportunidad de mercado: GSK estima que aproximadamente 21 millones de adultos en EE.UU. menores de 50 años presentan comorbilidades como EPOC, asma o enfermedades cardíacas que aumentan el riesgo de RSV, ampliando significativamente la población objetivo actual de la vacuna (mayores de 50 en riesgo).

Soporte clínico: La solicitud está respaldada por el estudio de Fase IIIb NCT06389487 (n = 1,458). En adultos de 18-49 años con mayor riesgo, los títulos de anticuerpos neutralizantes demostraron no inferioridad respecto a los �60 años y la seguridad/reactogenicidad fue consistente con los datos previos de Fase III usados para la aprobación inicial.

Cronograma regulatorio: Se espera una decisión de la FDA en la primera mitad de 2026. Se están realizando presentaciones paralelas en la UE y Japón, indicando una estrategia global coordinada de expansión.

Contexto estratégico: Arexvy ya cuenta con aprobación en más de 60 países para adultos �60 años y en más de 50 mercados para adultos de alto riesgo entre 50 y 59 años. La expansión exitosa de la indicación aseguraría una ventaja pionera en un segmento RSV con competencia limitada y podría acelerar el crecimiento de ingresos.

Limitaciones: El anuncio no incluye previsiones de ventas; el impacto comercial dependerá de la aprobación regulatoria, las recomendaciones ACIP y la adopción en el mundo real.

주요 개발 사항: 2025� 7� 14�, GSK plc� 미국 FDA가 RSV 백신� Arexvy� 적응증을 중증 RSV 위험 인자가 하나 이상 있는 18-49� 성인으로 확장하는 보충 신청서를 검� 대상으� 수락했다� 6-K 양식� 통해 보고했습니다.

시장 기회: GSK� 미국 � 50� 미만 성인 � 2,100� 명이 COPD, 천식 또는 심장 질환� 같은 동반질환� 가지� 있어 RSV 위험� 높아 백신� 현재 대� 인구(50� 이상 고위험군)� 크게 확대한다� 추정합니�.

임상 지�: � 신청은 3� IIIb 연구 NCT06389487(참가� � = 1,458)� 의해 뒷받침됩니다. 위험� 증가� 18-49� 성인에서 중화 항체 역가가 60� 이상� 비열등성� 충족했으�, 안전� � 반응성은 초기 승인� 사용� 이전 3� 데이터와 일치했습니다.

규제 일정: FDA 결정은 2026� 상반기에 예상됩니�. EU와 일본에서� 병행 제출� 진행 중이�, 이는 � 세계� 확장 전략� 일환임을 시사합니�.

전략� 맥락: Arexvy� 이미 60개국 이상에서 60� 이상 성인 대상으�, 50-59� 고위� 성인 대상으로는 50� 이상� 시장에서 승인� 받았습니�. 적응� 확장� 성공하면 경쟁� 제한� RSV 부문에� 선도� 위치� 확보하고 매출 성장 가속화� 기여� � 있습니다.

제한 사항: 발표에는 매출 전망� 포함되어 있지 않으�, 상업� 영향은 규제 승인, ACIP 권고 � 실제 사용률에 따라 달라집니�.

Développement clé : Le 14 juillet 2025, GSK plc a déposé un formulaire 6-K rapportant que la FDA américaine a accepté d'examiner une demande complémentaire visant à étendre l'indication de son vaccin RSV, Arexvy, aux adultes âgés de 18 à 49 ans présentant au moins un facteur de risque pour une forme sévère de RSV.

Opportunité de marché : GSK estime qu'environ 21 millions d'adultes américains de moins de 50 ans présentent des comorbidités telles que la BPCO, l'asthme ou des maladies cardiaques, augmentant ainsi significativement la population cible actuelle du vaccin (plus de 50 ans à risque).

Soutien clinique : Le dossier est appuyé par l'étude de phase IIIb NCT06389487 (n = 1 458). Chez les adultes de 18 à 49 ans à risque accru, les titres d'anticorps neutralisants ont démontré une non-infériorité par rapport à ceux des �60 ans et la sécurité/réactogénicité correspondait aux données de phase III antérieures utilisées pour l'approbation initiale.

Calendrier réglementaire : La décision de la FDA est attendue au premier semestre 2026. Des soumissions parallèles sont en cours dans l'UE et au Japon, indiquant une stratégie d'expansion mondiale coordonnée.

Contexte stratégique : Arexvy est déjà approuvé dans plus de 60 pays pour les adultes �60 ans et dans plus de 50 marchés pour les adultes à haut risque de 50 à 59 ans. Une extension d'indication réussie assurerait un avantage de premier entrant dans un segment RSV avec une concurrence limitée et pourrait accélérer la croissance des revenus.

Limitations : L'annonce ne contient pas de prévisions de ventes ; l'impact commercial dépendra de l'approbation réglementaire, des recommandations ACIP et de l'adoption dans la pratique réelle.

Wichtige Entwicklung: Am 14. Juli 2025 reichte GSK plc ein Formular 6-K ein und berichtete, dass die US-amerikanische FDA eine ergänzende Zulassungsanfrage zur Erweiterung der Indikation ihres RSV-Impfstoffs Arexvy für Erwachsene im Alter von 18 bis 49 Jahren mit mindestens einem Risikofaktor für schwere RSV-Erkrankungen zur Prüfung angenommen hat.

Marktchance: GSK schätzt, dass etwa 21 Millionen US-Erwachsene unter 50 Jahren Komorbiditäten wie COPD, Asthma oder Herzkrankheiten aufweisen, die das RSV-Risiko erhöhen und somit die derzeitige Zielpopulation des Impfstoffs (50+ Risikogruppe) deutlich vergrößern.

Klinische Unterstützung: Die Einreichung wird durch die Phase-IIIb-Studie NCT06389487 (n = 1.458) gestützt. Bei Erwachsenen im Alter von 18-49 Jahren mit erhöhtem Risiko erreichten die neutralisierenden Antikörpertiter die Nicht-Unterlegenheitskriterien gegenüber den �60-Jährigen, und Sicherheit/Reaktogenität entsprachen den früheren Phase-III-Daten, die für die Erstzulassung verwendet wurden.

Regulatorischer Zeitplan: Die FDA-Entscheidung wird für das erste Halbjahr 2026 erwartet. Parallel dazu laufen Einreichungen in der EU und Japan, was auf eine koordinierte globale Expansionsstrategie hinweist.

Strategischer Kontext: Arexvy ist bereits in über 60 Ländern für Erwachsene ab 60 Jahren und in über 50 Märkten für Hochrisiko-Erwachsene im Alter von 50-59 Jahren zugelassen. Eine erfolgreiche Indikationserweiterung würde einen First-Mover-Vorteil in einem RSV-Segment mit begrenztem Wettbewerb sichern und könnte das Umsatzwachstum beschleunigen.

ä԰ܲԲ: Die Bekanntgabe enthält keine Umsatzprognosen; die kommerziellen Auswirkungen hängen von der behördlichen Zulassung, den ACIP-Empfehlungen und der tatsächlichen Marktdurchdringung ab.

Positive
  • FDA acceptance of the supplemental application to cover high-risk adults 18-49 moves Arexvy closer to an expanded US label.
  • Large addressable population of approximately 21 million US adults offers meaningful incremental revenue potential.
  • Phase IIIb data showed non-inferior immunogenicity and consistent safety, lowering clinical risk.
  • Global expansion efforts in the EU and Japan underline a coordinated growth strategy.
Negative
  • No approval yet; FDA decision not expected until H1 2026, delaying revenue realisation.
  • Regulatory and ACIP uncertainties could restrict the final label or reimbursement, limiting uptake.
  • Absence of financial guidance leaves magnitude and timing of commercial impact unclear.

Insights

TL;DR: FDA review acceptance meaningfully widens Arexvy’s total addressable market; positive for growth momentum but approval risk remains.

The FDA’s willingness to evaluate Arexvy for high-risk adults 18-49 indicates clinical package adequacy and reduces regulatory uncertainty. A 21 million-patient US cohort could add a mid-single-digit billion-dollar sales opportunity by late-decade, assuming moderate uptake and competitive pricing. With Arexvy already commercialised in older populations, GSK benefits from established manufacturing, supply chains and provider familiarity, easing launch execution. Competitive threats from Pfizer and Moderna remain, yet first-mover status and a broader label could fortify share. Overall, the event is clearly impactful, albeit dependent on 2026 approval.

TL;DR: Submission accepted but outcome uncertain; investors should watch safety findings and ACIP stance before revising forecasts.

Acceptance of a supplemental BLA does not guarantee approval. The FDA will scrutinise immunogenicity data, reactogenicity in younger adults and post-marketing safety commitments. Timeline to H1 2026 lengthens visibility, and any label constraints could temper uptake. Additionally, ACIP recommendations will dictate reimbursement and real-world demand. While the news is directionally positive, risk-adjusted value should remain tempered until clearer regulatory signals emerge.

Sviluppo chiave: Il 14 luglio 2025 GSK plc ha presentato un modulo 6-K comunicando che la FDA statunitense ha accettato per la revisione una domanda supplementare per estendere l'indicazione del suo vaccino RSV, Arexvy, agli adulti di età compresa tra 18 e 49 anni con almeno un fattore di rischio per forme gravi di RSV.

Opportunità di mercato: GSK stima che circa 21 milioni di adulti statunitensi sotto i 50 anni presentino comorbidità come BPCO, asma o malattie cardiache che aumentano il rischio di RSV, ampliando significativamente la popolazione target attuale del vaccino (50+ a rischio).

Supporto clinico: La domanda è supportata dallo studio di Fase IIIb NCT06389487 (n = 1.458). Negli adulti 18-49 a rischio aumentato, i titoli di anticorpi neutralizzanti hanno dimostrato non inferiorità rispetto a quelli �60 anni e la sicurezza/reactogenicità è risultata in linea con i dati della precedente Fase III usata per l'approvazione iniziale.

Tempistiche regolatorie: La decisione della FDA è prevista per la prima metà del 2026. Sono in corso sottomissioni parallele nell'UE e in Giappone, indicando una strategia globale coordinata di espansione.

Contesto strategico: Arexvy è già approvato in oltre 60 paesi per adulti �60 anni e in più di 50 mercati per adulti ad alto rischio tra i 50 e 59 anni. L'espansione dell'indicazione assicurerebbe un vantaggio da pioniere in un segmento RSV con competizione limitata e potrebbe accelerare la crescita dei ricavi.

Limitazioni: L'annuncio non contiene previsioni di vendita; l'impatto commerciale dipenderà dall'approvazione regolatoria, dalle raccomandazioni ACIP e dall'adozione nel mondo reale.

Desarrollo clave: El 14 de julio de 2025, GSK plc presentó un Formulario 6-K informando que la FDA de EE.UU. ha aceptado para revisión una solicitud suplementaria para ampliar la indicación de su vacuna contra el RSV, Arexvy, a adultos de 18 a 49 años que tengan al menos un factor de riesgo para RSV grave.

Oportunidad de mercado: GSK estima que aproximadamente 21 millones de adultos en EE.UU. menores de 50 años presentan comorbilidades como EPOC, asma o enfermedades cardíacas que aumentan el riesgo de RSV, ampliando significativamente la población objetivo actual de la vacuna (mayores de 50 en riesgo).

Soporte clínico: La solicitud está respaldada por el estudio de Fase IIIb NCT06389487 (n = 1,458). En adultos de 18-49 años con mayor riesgo, los títulos de anticuerpos neutralizantes demostraron no inferioridad respecto a los �60 años y la seguridad/reactogenicidad fue consistente con los datos previos de Fase III usados para la aprobación inicial.

Cronograma regulatorio: Se espera una decisión de la FDA en la primera mitad de 2026. Se están realizando presentaciones paralelas en la UE y Japón, indicando una estrategia global coordinada de expansión.

Contexto estratégico: Arexvy ya cuenta con aprobación en más de 60 países para adultos �60 años y en más de 50 mercados para adultos de alto riesgo entre 50 y 59 años. La expansión exitosa de la indicación aseguraría una ventaja pionera en un segmento RSV con competencia limitada y podría acelerar el crecimiento de ingresos.

Limitaciones: El anuncio no incluye previsiones de ventas; el impacto comercial dependerá de la aprobación regulatoria, las recomendaciones ACIP y la adopción en el mundo real.

주요 개발 사항: 2025� 7� 14�, GSK plc� 미국 FDA가 RSV 백신� Arexvy� 적응증을 중증 RSV 위험 인자가 하나 이상 있는 18-49� 성인으로 확장하는 보충 신청서를 검� 대상으� 수락했다� 6-K 양식� 통해 보고했습니다.

시장 기회: GSK� 미국 � 50� 미만 성인 � 2,100� 명이 COPD, 천식 또는 심장 질환� 같은 동반질환� 가지� 있어 RSV 위험� 높아 백신� 현재 대� 인구(50� 이상 고위험군)� 크게 확대한다� 추정합니�.

임상 지�: � 신청은 3� IIIb 연구 NCT06389487(참가� � = 1,458)� 의해 뒷받침됩니다. 위험� 증가� 18-49� 성인에서 중화 항체 역가가 60� 이상� 비열등성� 충족했으�, 안전� � 반응성은 초기 승인� 사용� 이전 3� 데이터와 일치했습니다.

규제 일정: FDA 결정은 2026� 상반기에 예상됩니�. EU와 일본에서� 병행 제출� 진행 중이�, 이는 � 세계� 확장 전략� 일환임을 시사합니�.

전략� 맥락: Arexvy� 이미 60개국 이상에서 60� 이상 성인 대상으�, 50-59� 고위� 성인 대상으로는 50� 이상� 시장에서 승인� 받았습니�. 적응� 확장� 성공하면 경쟁� 제한� RSV 부문에� 선도� 위치� 확보하고 매출 성장 가속화� 기여� � 있습니다.

제한 사항: 발표에는 매출 전망� 포함되어 있지 않으�, 상업� 영향은 규제 승인, ACIP 권고 � 실제 사용률에 따라 달라집니�.

Développement clé : Le 14 juillet 2025, GSK plc a déposé un formulaire 6-K rapportant que la FDA américaine a accepté d'examiner une demande complémentaire visant à étendre l'indication de son vaccin RSV, Arexvy, aux adultes âgés de 18 à 49 ans présentant au moins un facteur de risque pour une forme sévère de RSV.

Opportunité de marché : GSK estime qu'environ 21 millions d'adultes américains de moins de 50 ans présentent des comorbidités telles que la BPCO, l'asthme ou des maladies cardiaques, augmentant ainsi significativement la population cible actuelle du vaccin (plus de 50 ans à risque).

Soutien clinique : Le dossier est appuyé par l'étude de phase IIIb NCT06389487 (n = 1 458). Chez les adultes de 18 à 49 ans à risque accru, les titres d'anticorps neutralisants ont démontré une non-infériorité par rapport à ceux des �60 ans et la sécurité/réactogénicité correspondait aux données de phase III antérieures utilisées pour l'approbation initiale.

Calendrier réglementaire : La décision de la FDA est attendue au premier semestre 2026. Des soumissions parallèles sont en cours dans l'UE et au Japon, indiquant une stratégie d'expansion mondiale coordonnée.

Contexte stratégique : Arexvy est déjà approuvé dans plus de 60 pays pour les adultes �60 ans et dans plus de 50 marchés pour les adultes à haut risque de 50 à 59 ans. Une extension d'indication réussie assurerait un avantage de premier entrant dans un segment RSV avec une concurrence limitée et pourrait accélérer la croissance des revenus.

Limitations : L'annonce ne contient pas de prévisions de ventes ; l'impact commercial dépendra de l'approbation réglementaire, des recommandations ACIP et de l'adoption dans la pratique réelle.

Wichtige Entwicklung: Am 14. Juli 2025 reichte GSK plc ein Formular 6-K ein und berichtete, dass die US-amerikanische FDA eine ergänzende Zulassungsanfrage zur Erweiterung der Indikation ihres RSV-Impfstoffs Arexvy für Erwachsene im Alter von 18 bis 49 Jahren mit mindestens einem Risikofaktor für schwere RSV-Erkrankungen zur Prüfung angenommen hat.

Marktchance: GSK schätzt, dass etwa 21 Millionen US-Erwachsene unter 50 Jahren Komorbiditäten wie COPD, Asthma oder Herzkrankheiten aufweisen, die das RSV-Risiko erhöhen und somit die derzeitige Zielpopulation des Impfstoffs (50+ Risikogruppe) deutlich vergrößern.

Klinische Unterstützung: Die Einreichung wird durch die Phase-IIIb-Studie NCT06389487 (n = 1.458) gestützt. Bei Erwachsenen im Alter von 18-49 Jahren mit erhöhtem Risiko erreichten die neutralisierenden Antikörpertiter die Nicht-Unterlegenheitskriterien gegenüber den �60-Jährigen, und Sicherheit/Reaktogenität entsprachen den früheren Phase-III-Daten, die für die Erstzulassung verwendet wurden.

Regulatorischer Zeitplan: Die FDA-Entscheidung wird für das erste Halbjahr 2026 erwartet. Parallel dazu laufen Einreichungen in der EU und Japan, was auf eine koordinierte globale Expansionsstrategie hinweist.

Strategischer Kontext: Arexvy ist bereits in über 60 Ländern für Erwachsene ab 60 Jahren und in über 50 Märkten für Hochrisiko-Erwachsene im Alter von 50-59 Jahren zugelassen. Eine erfolgreiche Indikationserweiterung würde einen First-Mover-Vorteil in einem RSV-Segment mit begrenztem Wettbewerb sichern und könnte das Umsatzwachstum beschleunigen.

ä԰ܲԲ: Die Bekanntgabe enthält keine Umsatzprognosen; die kommerziellen Auswirkungen hängen von der behördlichen Zulassung, den ACIP-Empfehlungen und der tatsächlichen Marktdurchdringung ab.

The information in this preliminary pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, underlying supplement, prospectus supplement and prospectus are not an offer to sell these securities, nor are they soliciting an offer to buy these securities, in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JULY 14, 2025

Citigroup Global Markets Holdings Inc.

July     , 2025

Medium-Term Senior Notes, Series N

Pricing Supplement No. 2025-USNCH27575

Filed Pursuant to Rule 424(b)(2)

Registration Statement Nos. 333-270327 and 333-270327-01

Autocallable Equity Linked Securities Linked to the Worst Performing of the Nasdaq-100 Index®, the Russell 2000® Index and the S&P 500® Index Due January 22, 2027

The securities offered by this pricing supplement are unsecured debt securities issued by Citigroup Global Markets Holdings Inc. and guaranteed by Citigroup Inc. The securities offer periodic coupon payments at an annualized rate that is generally higher than the yield on our conventional debt securities of the same maturity. In exchange for this higher yield, you must be willing to accept the risks that (i) the value of what you receive at maturity may be significantly less than the stated principal amount of your securities, and may be zero (excluding the final coupon payment), and (ii) the securities may be automatically called for redemption prior to maturity beginning on the first potential autocall date specified below. Each of these risks will depend solely on the performance of the worst performing of the underlyings specified below.

You will be subject to risks associated with each of the underlyings and will be negatively affected by adverse movements in any one of the underlyings. Although you will have downside exposure to the worst performing underlying, you will not receive dividends with respect to any underlying or participate in any appreciation of any underlying.

Investors in the securities must be willing to accept (i) an investment that may have limited or no liquidity and (ii) the risk of not receiving any payments due under the securities if we and Citigroup Inc. default on our obligations. All payments on the securities are subject to the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc.

 

KEY TERMS

Issuer:

Citigroup Global Markets Holdings Inc., a wholly owned subsidiary of Citigroup Inc.

Guarantee:

All payments due on the securities are fully and unconditionally guaranteed by Citigroup Inc.

Underlyings:

 

Underlying

Initial underlying value*

Final barrier value**

Nasdaq-100 Index®

 

 

Russell 2000® Index

 

 

S&P 500® Index

 

 

 

*For each underlying, its closing value on the pricing date

**For each underlying, 70.00% of its initial underlying value

Stated principal amount:

$1,000 per security

Pricing date:

July 21, 2025

Issue date:

July 24, 2025

Valuation date:

January 19, 2027, subject to postponement if such date is not a scheduled trading day or certain market disruption events occur

Maturity date:

Unless earlier redeemed, January 22, 2027

Coupon payments:

On each coupon payment date, unless previously redeemed, the securities will pay a coupon equal to at least 0.625% of the stated principal amount of the securities (equivalent to a coupon rate of at least 7.50% per annum) (to be determined on the pricing date).

Coupon payment dates:

The 22nd day of each calendar month beginning in August 2025. If any coupon payment date is not a business day, the payment to be made on that coupon payment date will be made on the next succeeding business day with the same force and effect as if made on that coupon payment date. No interest will accrue as a result of any delayed payment.

Payment at maturity:

If the securities are not automatically redeemed prior to maturity, you will receive at maturity for each security you then hold (in addition to the final coupon payment):

If the final underlying value of the worst performing underlying on the valuation date is greater than or equal to its final barrier value: $1,000

If the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value:

$1,000 + ($1,000 × the underlying return of the worst performing underlying on the valuation date)

If the securities are not automatically redeemed prior to maturity and the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value, you will receive significantly less than the stated principal amount of your securities, and possibly nothing (other than the final coupon payment), at maturity.

Listing:

The securities will not be listed on any securities exchange

Underwriter:

Citigroup Global Markets Inc. (“CGMI”), an affiliate of the issuer, acting as principal

Underwriting fee and issue price:

Issue price(1)

Underwriting fee(2)

Proceeds to issuer(3)

Per security:

$1,000.00

$19.50

$980.50

Total:

$

$

$

 

(Key Terms continued on next page)

(1) Citigroup Global Markets Holdings Inc. currently expects that the estimated value of the securities on the pricing date will be at least $925.50 per security, which will be less than the issue price. The estimated value of the securities is based on CGMI’s proprietary pricing models and our internal funding rate. It is not an indication of actual profit to CGMI or other of our affiliates, nor is it an indication of the price, if any, at which CGMI or any other person may be willing to buy the securities from you at any time after issuance. See “Valuation of the Securities” in this pricing supplement.

(2) CGMI will receive an underwriting fee of up to $19.50 for each security sold in this offering. The total underwriting fee and proceeds to issuer in the table above give effect to the actual total underwriting fee. For more information on the distribution of the securities, see “Supplemental Plan of Distribution” in this pricing supplement. In addition to the underwriting fee, CGMI and its affiliates may profit from expected hedging activity related to this offering, even if the value of the securities declines. See “Use of Proceeds and Hedging” in the accompanying prospectus.

(3) The per security proceeds to issuer indicated above represent the minimum per security proceeds to issuer for any security, assuming the maximum per security underwriting fee. As noted above, the underwriting fee is variable.

Investing in the securities involves risks not associated with an investment in conventional debt securities. See “Summary Risk Factors” beginning on page PS-5.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities or determined that this pricing supplement and the accompanying product supplement, underlying supplement, prospectus supplement and prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

You should read this pricing supplement together with the accompanying product supplement, underlying supplement, prospectus supplement and prospectus, which can be accessed via the hyperlinks below:

Product Supplement No. EA-02-10 dated March 7, 2023Underlying Supplement No. 11 dated March 7, 2023
Prospectus Supplement and Prospectus each dated March 7, 2023

The securities are not bank deposits and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency, nor are they obligations of, or guaranteed by, a bank.

 


 

Citigroup Global Markets Holdings Inc.

 

 

KEY TERMS (continued)

Automatic early redemption:

If, on any potential autocall date, the closing value of the worst performing underlying on that potential autocall date is greater than or equal to  its initial underlying value, each security you then hold will be automatically called on that potential autocall date for redemption on the immediately following coupon payment date for an amount in cash equal to $1,000 plus the related coupon payment. The automatic early redemption feature may significantly limit your potential return on the securities. If the worst performing underlying performs in a way that would otherwise be favorable, the securities are likely to be automatically called for redemption prior to maturity, cutting short your opportunity to receive coupon payments. The securities may be automatically called for redemption as early as the first potential autocall date specified below.

Potential autocall dates:

January 16, 2026, February 18, 2026, March 18, 2026, April 17, 2026, May 19, 2026, June 16, 2026, July 17, 2026, August 19, 2026, September 17, 2026, October 19, 2026, November 18, 2026 and December 17, 2026, each subject to postponement as if such date were the valuation date as described in the accompanying product supplement. If a scheduled potential autocall date is postponed by one or more business days, the immediately following coupon payment date will be postponed by an equal number of business days.

Final underlying value:

For each underlying, its closing value on the valuation date

Worst performing underlying:

For any date, the underlying with the lowest underlying return determined as of that date

Underlying return:

For each underlying on any date, (i) its closing value on that date minus its initial underlying value, divided by (ii) its initial underlying value

CUSIP / ISIN:

17333LLW3 / US17333LLW36

 


 

Citigroup Global Markets Holdings Inc.

 

 

Additional Information

The terms of the securities are set forth in the accompanying product supplement, prospectus supplement and prospectus, as supplemented by this pricing supplement. The accompanying product supplement, prospectus supplement and prospectus contain important disclosures that are not repeated in this pricing supplement. For example, the accompanying product supplement contains important information about how the closing value of each underlying will be determined and about adjustments that may be made to the terms of the securities upon the occurrence of market disruption events and other specified events with respect to each underlying. The accompanying underlying supplement contains information about each underlying that is not repeated in this pricing supplement. It is important that you read the accompanying product supplement, underlying supplement, prospectus supplement and prospectus together with this pricing supplement before deciding whether to invest in the securities. Certain terms used but not defined in this pricing supplement are defined in the accompanying product supplement.

 


 

Citigroup Global Markets Holdings Inc.

 

 

Hypothetical Examples

The examples below illustrate how to determine the payment at maturity on the securities, assuming the securities are not automatically redeemed prior to maturity. You should understand that the term of the securities, and your opportunity to receive the coupon payments on the securities, may be limited by the automatic early redemption feature of the securities, which is not reflected in the examples below. The outcomes illustrated below are not exhaustive, and your actual payment at maturity on the securities (if the securities are not earlier automatically redeemed) may differ from any example illustrated below. The examples are solely for illustrative purposes, do not show all possible outcomes and are not a prediction of any payment that may be made on the securities.

The examples below are based on the following hypothetical values and do not reflect the actual initial underlying values or final barrier values of the underlyings. For the actual initial underlying value and final barrier value of each underlying, see the cover page of this pricing supplement. We have used these hypothetical values, rather than the actual values, to simplify the calculations and aid understanding of how the securities work. However, you should understand that the actual payments on the securities will be calculated based on the actual initial underlying value and final barrier value of each underlying, and not the hypothetical values indicated below. For ease of analysis, figures below have been rounded. The examples below assume that the coupon rate is set at the lowest value indicated on the cover page of this pricing supplement. The actual coupon rate will be determined on the pricing date.

 

Underlying

Hypothetical initial underlying value

Hypothetical final barrier value

Nasdaq-100 Index®

100.00

70.00 (70.00% of its hypothetical initial underlying value)

Russell 2000® Index

100.00

70.00 (70.00% of its hypothetical initial underlying value)

S&P 500® Index

100.00

70.00 (70.00% of its hypothetical initial underlying value)

 

 

 

 

Hypothetical final underlying value of the Nasdaq-100 Index®

Hypothetical final underlying value of the Russell 2000® Index

Hypothetical final underlying value of the S&P 500® Index

Hypothetical payment at maturity per $1,000.00 security (excluding the final coupon payment)

Example 1

110
(underlying return =
(110 - 100) / 100 = 10%)

120
(underlying return =
(120 - 100) / 100 = 20%)

155
(underlying return =
(155 - 100) / 100 = 55%)

$1,000.00

Example 2

110
(underlying return =
(110 - 100) / 100 = 10%)

110
(underlying return =
(110 - 100) / 100 = 10%)

45
(underlying return =
(45 - 100) / 100 = -55%)

$450.00

Example 3

20
(underlying return =
(20 - 100) / 100 = -80%)

90
(underlying return =
(90 - 100) / 100 = -10%)

40
(underlying return =
(40 - 100) / 100 = -60%)

$200.00

 

Example 1: On the valuation date, the Nasdaq-100 Index® has the lowest underlying return and, therefore, is the worst performing underlying on the valuation date. In this scenario, the final underlying value of the worst performing underlying on the valuation date is greater than its final barrier value. Accordingly, at maturity, you would receive the stated principal amount of the securities plus the final coupon payment. You would not participate in the appreciation of any of the underlyings.

Example 2: On the valuation date, the S&P 500® Index has the lowest underlying return and, therefore, is the worst performing underlying on the valuation date. In this scenario, the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value. Accordingly, at maturity, you would receive a payment per security (excluding the final coupon payment) calculated as follows:

Payment at maturity = $1,000.00 + ($1,000.00 × the underlying return of the worst performing underlying on the valuation date)

= $1,000.00 + ($1,000.00 × -55.00%)

= $1,000.00 + -$550.00

= $450.00

In this scenario, because the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value, you would lose a significant portion of your investment in the securities.

Example 3: On the valuation date, the Nasdaq-100 Index® has the lowest underlying return and, therefore, is the worst performing underlying on the valuation date. In this scenario, the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value. Accordingly, at maturity, you would receive a payment per security (excluding the final coupon payment) calculated as follows:

Payment at maturity = $1,000.00 + ($1,000.00 × the underlying return of the worst performing underlying on the valuation date)

= $1,000.00 + ($1,000.00 × -80.00%)

= $1,000.00 + -$800.00

= $200.00

In this scenario, because the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value, you would lose a significant portion of your investment in the securities.


 

Citigroup Global Markets Holdings Inc.

 

 

Summary Risk Factors

An investment in the securities is significantly riskier than an investment in conventional debt securities. The securities are subject to all of the risks associated with an investment in our conventional debt securities (guaranteed by Citigroup Inc.), including the risk that we and Citigroup Inc. may default on our obligations under the securities, and are also subject to risks associated with each underlying. Accordingly, the securities are suitable only for investors who are capable of understanding the complexities and risks of the securities. You should consult your own financial, tax and legal advisors as to the risks of an investment in the securities and the suitability of the securities in light of your particular circumstances.

The following is a summary of certain key risk factors for investors in the securities. You should read this summary together with the more detailed description of risks relating to an investment in the securities contained in the section “Risk Factors Relating to the Securities” beginning on page EA-7 in the accompanying product supplement. You should also carefully read the risk factors included in the accompanying prospectus supplement and in the documents incorporated by reference in the accompanying prospectus, including Citigroup Inc.’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, which describe risks relating to the business of Citigroup Inc. more generally.

Citigroup Inc. will release quarterly earnings on July 15, 2025, which is during the marketing period and prior to the pricing date of these securities.

You may lose a significant portion or all of your investment. Unlike conventional debt securities, the securities do not provide for the repayment of the stated principal amount at maturity in all circumstances. If the securities are not automatically redeemed prior to maturity, your payment at maturity will depend on the final underlying value of the worst performing underlying on the valuation date. If the final underlying value of the worst performing underlying on the valuation date is less than its final barrier value, you will lose 1% of the stated principal amount of your securities for every 1% by which the worst performing underlying on the valuation date has declined from its initial underlying value. There is no minimum payment at maturity on the securities (excluding the final coupon payment), and you may lose up to all of your investment.

Higher coupon rates are associated with greater risk. The securities offer coupon payments at an annualized rate that is generally higher than the yield on our conventional debt securities of the same maturity. This higher potential yield is associated with greater levels of expected risk as of the pricing date for the securities, including the risk that the value of what you receive at maturity may be significantly less than the stated principal amount of your securities and may be zero. The volatility of, and correlation between, the closing values of the underlyings are important factors affecting these risks. Greater expected volatility of, and lower expected correlation between, the closing values of the underlyings as of the pricing date may result in a higher coupon rate, but would also represent a greater expected likelihood as of the pricing date that the final underlying value of the worst performing underlying on the valuation date will be less than its final barrier value, such that you will not be repaid the stated principal amount of your securities at maturity.

The securities are subject to heightened risk because they have multiple underlyings. The securities are more risky than similar investments that may be available with only one underlying. With multiple underlyings, there is a greater chance that any one underlying will perform poorly, adversely affecting your return on the securities.

The securities are subject to the risks of each of the underlyings and will be negatively affected if any one underlying performs poorly. You are subject to risks associated with each of the underlyings. If any one underlying performs poorly, you will be negatively affected. The securities are not linked to a basket composed of the underlyings, where the blended performance of the underlyings would be better than the performance of the worst performing underlying alone. Instead, you are subject to the full risks of whichever of the underlyings is the worst performing underlying.

You will not benefit in any way from the performance of any better performing underlying. The return on the securities depends solely on the performance of the worst performing underlying, and you will not benefit in any way from the performance of any better performing underlying.

You will be subject to risks relating to the relationship between the underlyings. It is preferable from your perspective for the underlyings to be correlated with each other, in the sense that their closing values tend to increase or decrease at similar times and by similar magnitudes. By investing in the securities, you assume the risk that the underlyings will not exhibit this relationship. The less correlated the underlyings, the more likely it is that any one of the underlyings will perform poorly over the term of the securities. All that is necessary for the securities to perform poorly is for one of the underlyings to perform poorly. It is impossible to predict what the relationship between the underlyings will be over the term of the securities. The underlyings differ in significant ways and, therefore, may not be correlated with each other.

The securities may be automatically redeemed prior to maturity, limiting your opportunity to receive coupon payments. On any potential autocall date, the securities will be automatically called for redemption if the closing value of the worst performing underlying on that potential autocall date is greater than or equal to its initial underlying value. As a result, if the worst performing underlying performs in a way that would otherwise be favorable, the securities are likely to be automatically redeemed, cutting short your opportunity to receive coupon payments. If the securities are automatically redeemed prior to maturity, you may not be able to reinvest your funds in another investment that provides a similar yield with a similar level of risk.

The securities offer downside exposure to the worst performing underlying, but no upside exposure to any underlying. You will not participate in any appreciation in the value of any underlying over the term of the securities. Consequently, your return on the securities will be limited to the coupon payments you receive and may be significantly less than the return on any underlying over the term of the securities. In addition, as an investor in the securities, you will not receive any dividends or other distributions or have any other rights with respect to any of the underlyings.

The performance of the securities will depend on the closing values of the underlyings solely on the potential autocall dates and the valuation date, which makes the securities particularly sensitive to volatility in the closing values of the underlyings. If


 

Citigroup Global Markets Holdings Inc.

 

 

the securities are not automatically redeemed prior to maturity, the amount you receive at maturity will depend solely on the closing value of the worst performing underlying on the valuation date. Whether the securities will be automatically redeemed prior to maturity will depend on the closing values of the underlyings solely on each potential autocall date. As a result, because the performance of the securities depends on the closing values of the underlyings on a limited number of dates, the securities will be particularly sensitive to the volatility of the underlyings on or near the potential autocall dates and the valuation date. You should understand that the underlyings have historically been highly volatile.

The securities are subject to the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc. If we default on our obligations under the securities and Citigroup Inc. defaults on its guarantee obligations, you may not receive anything owed to you under the securities.

The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity. The securities will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. CGMI currently intends to make a secondary market in relation to the securities and to provide an indicative bid price for the securities on a daily basis. Any indicative bid price for the securities provided by CGMI will be determined in CGMI’s sole discretion, taking into account prevailing market conditions and other relevant factors, and will not be a representation by CGMI that the securities can be sold at that price, or at all. CGMI may suspend or terminate making a market and providing indicative bid prices without notice, at any time and for any reason. If CGMI suspends or terminates making a market, there may be no secondary market at all for the securities because it is likely that CGMI will be the only broker-dealer that is willing to buy your securities prior to maturity. Accordingly, an investor must be prepared to hold the securities until maturity.

The estimated value of the securities on the pricing date, based on CGMI’s proprietary pricing models and our internal funding rate, will be less than the issue price. The difference is attributable to certain costs associated with selling, structuring and hedging the securities that are included in the issue price. These costs include (i) any selling concessions or other fees paid in connection with the offering of the securities, (ii) hedging and other costs incurred by us and our affiliates in connection with the offering of the securities and (iii) the expected profit (which may be more or less than actual profit) to CGMI or other of our affiliates in connection with hedging our obligations under the securities. These costs adversely affect the economic terms of the securities because, if they were lower, the economic terms of the securities would be more favorable to you. The economic terms of the securities are also likely to be adversely affected by the use of our internal funding rate, rather than our secondary market rate, to price the securities. See “The estimated value of the securities would be lower if it were calculated based on our secondary market rate” below.

The estimated value of the securities was determined for us by our affiliate using proprietary pricing models. CGMI derived the estimated value disclosed on the cover page of this pricing supplement from its proprietary pricing models. In doing so, it may have made discretionary judgments about the inputs to its models, such as the volatility of, and correlation between, the closing values of the underlyings, dividend yields on the underlyings and interest rates. CGMI’s views on these inputs may differ from your or others’ views, and as an underwriter in this offering, CGMI’s interests may conflict with yours. Both the models and the inputs to the models may prove to be wrong and therefore not an accurate reflection of the value of the securities. Moreover, the estimated value of the securities set forth on the cover page of this pricing supplement may differ from the value that we or our affiliates may determine for the securities for other purposes, including for accounting purposes. You should not invest in the securities because of the estimated value of the securities. Instead, you should be willing to hold the securities to maturity irrespective of the initial estimated value.

The estimated value of the securities would be lower if it were calculated based on our secondary market rate. The estimated value of the securities included in this pricing supplement is calculated based on our internal funding rate, which is the rate at which we are willing to borrow funds through the issuance of the securities. Our internal funding rate is generally lower than our secondary market rate, which is the rate that CGMI will use in determining the value of the securities for purposes of any purchases of the securities from you in the secondary market. If the estimated value included in this pricing supplement were based on our secondary market rate, rather than our internal funding rate, it would likely be lower. We determine our internal funding rate based on factors such as the costs associated with the securities, which are generally higher than the costs associated with conventional debt securities, and our liquidity needs and preferences. Our internal funding rate is not an interest rate that is payable on the securities.

Because there is not an active market for traded instruments referencing our outstanding debt obligations, CGMI determines our secondary market rate based on the market price of traded instruments referencing the debt obligations of Citigroup Inc., our parent company and the guarantor of all payments due on the securities, but subject to adjustments that CGMI makes in its sole discretion. As a result, our secondary market rate is not a market-determined measure of our creditworthiness, but rather reflects the market’s perception of our parent company’s creditworthiness as adjusted for discretionary factors such as CGMI’s preferences with respect to purchasing the securities prior to maturity.

The estimated value of the securities is not an indication of the price, if any, at which CGMI or any other person may be willing to buy the securities from you in the secondary market. Any such secondary market price will fluctuate over the term of the securities based on the market and other factors described in the next risk factor. Moreover, unlike the estimated value included in this pricing supplement, any value of the securities determined for purposes of a secondary market transaction will be based on our secondary market rate, which will likely result in a lower value for the securities than if our internal funding rate were used. In addition, any secondary market price for the securities will be reduced by a bid-ask spread, which may vary depending on the aggregate stated principal amount of the securities to be purchased in the secondary market transaction, and the expected cost of unwinding related hedging transactions. As a result, it is likely that any secondary market price for the securities will be less than the issue price.

The value of the securities prior to maturity will fluctuate based on many unpredictable factors. The value of your securities prior to maturity will fluctuate based on the closing values of the underlyings, the volatility of, and correlation between, the closing values of the underlyings, dividend yields on the underlyings, interest rates generally, the time remaining to maturity and our and Citigroup Inc.’s creditworthiness, as reflected in our secondary market rate, among other factors described under “Risk Factors Relating to the


 

Citigroup Global Markets Holdings Inc.

 

 

Securities—Risk Factors Relating to All Securities—The value of your securities prior to maturity will fluctuate based on many unpredictable factors” in the accompanying product supplement. Changes in the closing values of the underlyings may not result in a comparable change in the value of your securities. You should understand that the value of your securities at any time prior to maturity may be significantly less than the issue price.

Immediately following issuance, any secondary market bid price provided by CGMI, and the value that will be indicated on any brokerage account statements prepared by CGMI or its affiliates, will reflect a temporary upward adjustment. The amount of this temporary upward adjustment will steadily decline to zero over the temporary adjustment period. See “Valuation of the Securities” in this pricing supplement.

The Russell 2000® Index is subject to risks associated with small capitalization stocks. The stocks that constitute the Russell 2000® Index are issued by companies with relatively small market capitalization. The stock prices of smaller companies may be more volatile than stock prices of large capitalization companies. These companies tend to be less well-established than large market capitalization companies. Small capitalization companies may be less able to withstand adverse economic, market, trade and competitive conditions relative to larger companies. Small capitalization companies are less likely to pay dividends on their stocks, and the presence of a dividend payment could be a factor that limits downward stock price pressure under adverse market conditions.

Our offering of the securities is not a recommendation of any underlying. The fact that we are offering the securities does not mean that we believe that investing in an instrument linked to the underlyings is likely to achieve favorable returns. In fact, as we are part of a global financial institution, our affiliates may have positions (including short positions) in the underlyings or in instruments related to the underlyings, and may publish research or express opinions, that in each case are inconsistent with an investment linked to the underlyings. These and other activities of our affiliates may affect the closing values of the underlyings in a way that negatively affects the value of and your return on the securities.

The closing value of an underlying may be adversely affected by our or our affiliates’ hedging and other trading activities. We expect to hedge our obligations under the securities through CGMI or other of our affiliates, who may take positions in the underlyings or in financial instruments related to the underlyings and may adjust such positions during the term of the securities. Our affiliates also take positions in the underlyings or in financial instruments related to the underlyings on a regular basis (taking long or short positions or both), for their accounts, for other accounts under their management or to facilitate transactions on behalf of customers. These activities could affect the closing values of the underlyings in a way that negatively affects the value of and your return on the securities. They could also result in substantial returns for us or our affiliates while the value of the securities declines.

We and our affiliates may have economic interests that are adverse to yours as a result of our affiliates’ business activities. Our affiliates engage in business activities with a wide range of companies. These activities include extending loans, making and facilitating investments, underwriting securities offerings and providing advisory services. These activities could involve or affect the underlyings in a way that negatively affects the value of and your return on the securities. They could also result in substantial returns for us or our affiliates while the value of the securities declines. In addition, in the course of this business, we or our affiliates may acquire non-public information, which will not be disclosed to you.

The calculation agent, which is an affiliate of ours, will make important determinations with respect to the securities. If certain events occur during the term of the securities, such as market disruption events and other events with respect to an underlying, CGMI, as calculation agent, will be required to make discretionary judgments that could significantly affect your return on the securities. In making these judgments, the calculation agent’s interests as an affiliate of ours could be adverse to your interests as a holder of the securities. See “Risk Factors Relating to the Securities—Risk Factors Relating to All Securities—The calculation agent, which is an affiliate of ours, will make important determinations with respect to the securities” in the accompanying product supplement.

Changes that affect the underlyings may affect the value of your securities. The sponsors of the underlyings may at any time make methodological changes or other changes in the manner in which they operate that could affect the values of the underlyings. We are not affiliated with any such underlying sponsor and, accordingly, we have no control over any changes any such sponsor may make. Such changes could adversely affect the performance of the underlyings and the value of and your return on the securities.

The U.S. federal tax consequences of an investment in the securities are unclear. There is no direct legal authority regarding the proper U.S. federal tax treatment of the securities, and we do not plan to request a ruling from the Internal Revenue Service (the “IRS”). Consequently, significant aspects of the tax treatment of the securities are uncertain, and the IRS or a court might not agree with the treatment of the securities as described in “United States Federal Tax Considerations” below. If the IRS were successful in asserting an alternative treatment of the securities, the tax consequences of the ownership and disposition of the securities might be materially and adversely affected. Moreover, future legislation, Treasury regulations or IRS guidance could adversely affect the U.S. federal tax treatment of the securities, possibly retroactively.

As described in “United States Federal Tax Considerations” below, in connection with any information reporting requirements we may have in respect of the securities under applicable law, we intend to treat a portion of each coupon payment as attributable to interest and the remainder to option premium. However, in light of the uncertain treatment of the securities, it is possible that other persons having withholding or information reporting responsibility in respect of the securities may treat a security differently, for instance, by treating the entire coupon payment as ordinary income at the time received or accrued by a holder and/or treating some or all of each coupon payment on a security to a non-U.S. investor as subject to withholding tax at a rate of 30%.

If withholding applies to the securities, we will not be required to pay any additional amounts with respect to amounts withheld.


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the Nasdaq-100 Index®

The Nasdaq-100 Index® is a modified market capitalization-weighted index of stocks of the 100 largest non-financial companies listed on the Nasdaq Stock Market. All stocks included in the Nasdaq-100 Index® are traded on a major U.S. exchange. The Nasdaq-100 Index® was developed by the Nasdaq Stock Market, Inc. and is calculated, maintained and published by Nasdaq, Inc.

Please refer to the section “Equity Index Descriptions— The Nasdaq-100 Index®” in the accompanying underlying supplement for additional information.

We have derived all information regarding the Nasdaq-100 Index® from publicly available information and have not independently verified any information regarding the Nasdaq-100 Index®. This pricing supplement relates only to the securities and not to the Nasdaq-100 Index®. We make no representation as to the performance of the Nasdaq-100 Index® over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the Nasdaq-100 Index® is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the Nasdaq-100 Index® on July 11, 2025 was 22,780.60.

The graph below shows the closing value of the Nasdaq-100 Index® for each day such value was available from January 2, 2015 to July 11, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

Nasdaq-100 Index® – Historical Closing Values
January 2, 2015 to July 11, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the Russell 2000® Index

The Russell 2000® Index is designed to track the performance of the small capitalization segment of the U.S. equity market. All stocks included in the Russell 2000® Index are traded on a major U.S. exchange. It is calculated and maintained by FTSE Russell.

Please refer to the section “Equity Index Descriptions— The Russell Indices” in the accompanying underlying supplement for additional information.

We have derived all information regarding the Russell 2000® Index from publicly available information and have not independently verified any information regarding the Russell 2000® Index. This pricing supplement relates only to the securities and not to the Russell 2000® Index. We make no representation as to the performance of the Russell 2000® Index over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the Russell 2000® Index is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the Russell 2000® Index on July 11, 2025 was 2,234.827.

The graph below shows the closing value of the Russell 2000® Index for each day such value was available from January 2, 2015 to July 11, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

Russell 2000® Index – Historical Closing Values
January 2, 2015 to July 11, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

Information About the S&P 500® Index

The S&P 500® Index consists of the common stocks of 500 issuers selected to provide a performance benchmark for the large capitalization segment of the U.S. equity markets. It is calculated and maintained by S&P Dow Jones Indices LLC.

Please refer to the section “Equity Index Descriptions— The S&P U.S. Indices” in the accompanying underlying supplement for additional information.

We have derived all information regarding the S&P 500® Index from publicly available information and have not independently verified any information regarding the S&P 500® Index. This pricing supplement relates only to the securities and not to the S&P 500® Index. We make no representation as to the performance of the S&P 500® Index over the term of the securities.

The securities represent obligations of Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) only. The sponsor of the S&P 500® Index is not involved in any way in this offering and has no obligation relating to the securities or to holders of the securities.

Historical Information

The closing value of the S&P 500® Index on July 11, 2025 was 6,259.75.

The graph below shows the closing value of the S&P 500® Index for each day such value was available from January 2, 2015 to July 11, 2025. We obtained the closing values from Bloomberg L.P., without independent verification. You should not take historical closing values as an indication of future performance.

S&P 500® Index – Historical Closing Values
January 2, 2015 to July 11, 2025

 


 

Citigroup Global Markets Holdings Inc.

 

 

United States Federal Tax Considerations

You should read carefully the discussion under “United States Federal Tax Considerations” and “Risk Factors Relating to the Securities” in the accompanying product supplement and “Summary Risk Factors” in this pricing supplement.

Due to the lack of any controlling legal authority, there is substantial uncertainty regarding the U.S. federal tax consequences of an investment in the securities. In connection with any information reporting requirements we may have in respect of the securities under applicable law, we intend (in the absence of an administrative determination or judicial ruling to the contrary) to treat a security as a put option (the “Put Option”) written by you with respect to the underlying shares, secured by a cash deposit equal to the stated principal amount of the security (the “Deposit”). In the opinion of our counsel, Davis Polk & Wardwell LLP, this treatment of the securities is reasonable under current law; however, our counsel has advised us that it is unable to conclude affirmatively that this treatment is more likely than not to be upheld, and that alternative treatments are possible. Moreover, our counsel’s opinion is based on market conditions as of the date of this preliminary pricing supplement and is subject to confirmation on the pricing date. Under this treatment:

a portion of each coupon payment made with respect to the securities will be attributable to interest on the Deposit; and

the remainder will represent premium attributable to your grant of the Put Option (“Put Premium”).

We will specify in the final pricing supplement the portion of each coupon payment that we will allocate to interest on the Deposit and to Put Premium, respectively.

Assuming the treatment of a security as a Put Option and a Deposit is respected, amounts treated as interest on the Deposit should be taxed as ordinary interest income, while the Put Premium should not be taken into account prior to maturity or disposition of the securities. See “United States Federal Tax Considerations—Tax Consequences to U.S. Holders” in the accompanying product supplement.

We do not plan to request a ruling from the IRS regarding the treatment of the securities. An alternative characterization of the securities could materially and adversely affect the tax consequences of ownership and disposition of the securities, including the timing and character of income recognized. In addition, the U.S. Treasury Department and the IRS requested comments on various issues regarding the U.S. federal income tax treatment of “prepaid forward contracts” and similar financial instruments and have indicated that such transactions may be the subject of future regulations or other guidance. Furthermore, members of Congress have proposed legislative changes to the tax treatment of derivative contracts. Any legislation, Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive effect. You should consult your tax adviser regarding possible alternative tax treatments of the securities and potential changes in applicable law.

Non-U.S. Holders. Subject to the discussions below and in the section of the accompanying product supplement entitled “United States Federal Tax Considerations,” if you are a Non-U.S. Holder (as defined in the accompanying product supplement) of the securities, under current law you generally should not be subject to U.S. federal withholding or income tax in respect of any amount paid to you with respect to the securities, provided that (i) income in respect of the securities is not effectively connected with your conduct of a trade or business in the United States, and (ii) you comply with the applicable certification requirements.

As discussed under “United States Federal Tax Considerations— Tax Consequences to Non-U.S. Holders— Dividend Equivalents under Section 871(m) of the Code” in the accompanying product supplement, Section 871(m) of the Internal Revenue Code of 1986, as amended, and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities (“Underlying Securities”) or indices that include Underlying Securities. Section 871(m) generally applies to instruments that substantially replicate the economic performance of one or more Underlying Securities, as determined based on tests set forth in the applicable Treasury regulations. However, the regulations, as modified by an IRS notice, exempt financial instruments issued prior to January 1, 2027 that do not have a “delta” of one. Based on the terms of the securities and representations provided by us as of the date of this preliminary pricing supplement, our counsel is of the opinion that the securities should not be treated as transactions that have a “delta” of one within the meaning of the regulations with respect to any Underlying Security and, therefore, should not be subject to withholding tax under Section 871(m). However, the final determination regarding the treatment of the securities under Section 871(m) will be made as of the pricing date for the securities, and it is possible that the securities will be subject to withholding tax under Section 871(m) based on the circumstances as of that date.

A determination that the securities are not subject to Section 871(m) is not binding on the IRS, and the IRS may disagree with this treatment. Moreover, Section 871(m) is complex and its application may depend on your particular circumstances, including your other transactions. You should consult your tax adviser regarding the potential application of Section 871(m) to the securities.

While we currently do not intend to withhold on payments on the securities to Non-U.S. Holders (subject to compliance with the applicable certification requirements and the discussion in the accompanying product supplement regarding “FATCA”), in light of the uncertain treatment of the securities other persons having withholding or information reporting responsibility in respect of the securities may treat some or all of each coupon payment on a security as subject to withholding tax at a rate of 30%. Moreover, it is possible that in the future we may determine that we should withhold at a rate of 30% on coupon payments on the securities. We will not be required to pay any additional amounts with respect to amounts withheld.

You should read the section entitled “United States Federal Tax Considerations” in the accompanying product supplement. The preceding discussion, when read in combination with that section, constitutes the full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of owning and disposing of the securities.

You should also consult your tax adviser regarding all aspects of the U.S. federal income and estate tax consequences of an investment in the securities and any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.


 

Citigroup Global Markets Holdings Inc.

 

 

Supplemental Plan of Distribution

CGMI, an affiliate of Citigroup Global Markets Holdings Inc. and the underwriter of the sale of the securities, is acting as principal and will receive an underwriting fee of up to $19.50 for each security sold in this offering. The actual underwriting fee will be equal to the selling concession provided to selected dealers, as described in this paragraph. From this underwriting fee, CGMI will pay selected dealers not affiliated with CGMI a variable selling concession of up to $19.50 for each security they sell. For the avoidance of doubt, any fees or selling concessions described in this pricing supplement will not be rebated if the securities are automatically redeemed prior to maturity.

See “Plan of Distribution; Conflicts of Interest” in the accompanying product supplement and “Plan of Distribution” in each of the accompanying prospectus supplement and prospectus for additional information.

Valuation of the Securities

CGMI calculated the estimated value of the securities set forth on the cover page of this pricing supplement based on proprietary pricing models. CGMI’s proprietary pricing models generated an estimated value for the securities by estimating the value of a hypothetical package of financial instruments that would replicate the payout on the securities, which consists of a fixed-income bond (the “bond component”) and one or more derivative instruments underlying the economic terms of the securities (the “derivative component”). CGMI calculated the estimated value of the bond component using a discount rate based on our internal funding rate. CGMI calculated the estimated value of the derivative component based on a proprietary derivative-pricing model, which generated a theoretical price for the instruments that constitute the derivative component based on various inputs, including the factors described under “Summary Risk Factors—The value of the securities prior to maturity will fluctuate based on many unpredictable factors” in this pricing supplement, but not including our or Citigroup Inc.’s creditworthiness. These inputs may be market-observable or may be based on assumptions made by CGMI in its discretionary judgment.

The estimated value of the securities is a function of the terms of the securities and the inputs to CGMI’s proprietary pricing models.  As of the date of this preliminary pricing supplement, it is uncertain what the estimated value of the securities will be on the pricing date because certain terms of the securities have not yet been fixed and because it is uncertain what the values of the inputs to CGMI’s proprietary pricing models will be on the pricing date.

For a period of approximately three months following issuance of the securities, the price, if any, at which CGMI would be willing to buy the securities from investors, and the value that will be indicated for the securities on any brokerage account statements prepared by CGMI or its affiliates (which value CGMI may also publish through one or more financial information vendors), will reflect a temporary upward adjustment from the price or value that would otherwise be determined. This temporary upward adjustment represents a portion of the hedging profit expected to be realized by CGMI or its affiliates over the term of the securities. The amount of this temporary upward adjustment will decline to zero on a straight-line basis over the three-month temporary adjustment period. However, CGMI is not obligated to buy the securities from investors at any time.  See “Summary Risk Factors—The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity.”

Contact

Clients may contact their local brokerage representative. Third-party distributors may contact Citi Structured Investment Sales at (212) 723-7005.

© 2025 Citigroup Global Markets Inc. All rights reserved. Citi and Citi and Arc Design are trademarks and service marks of Citigroup Inc. or its affiliates and are used and registered throughout the world.

FAQ

What did GSK (GSK) announce in its July 2025 Form 6-K?

The company reported that the FDA accepted its application to expand Arexvy’s indication to high-risk adults aged 18-49.

How large is the potential US market for Arexvy in adults 18-49?

GSK cites roughly 21 million US adults under 50 with at least one risk factor for severe RSV infection.

What trial data support the expanded indication?

Phase IIIb study NCT06389487 (n = 1,458) met non-inferiority for RSV-A and RSV-B neutralising antibodies and showed safety consistent with prior trials.

When is the FDA decision expected?

GSK anticipates an FDA ruling in H1 2026.

Is Arexvy already approved for other age groups?

Yes, it is authorised in the US for adults �60 and for high-risk adults 50-59, and in >60 countries for older adults.

Is GSK seeking approvals outside the United States?

The company is pursuing similar label expansions in the European Economic Area and Japan.
Citigroup Inc

NYSE:C

C Rankings

C Latest News

C Latest SEC Filings

C Stock Data

176.71B
1.83B
1.01%
76.85%
1.81%
Banks - Diversified
National Commercial Banks
United States
NEW YORK